Risperidone

As a leader in neuroscience, Teva remains committed to helping address unmet needs in the treatment of schizophrenia through scientific and clinical advances that support optimal treatment options and decisions for patients and HCPsNew data demonstrate switching to UZEDY at four weeks after the last dose of once-monthly RBP-7000 provided the most comparable pharmacokinetic (PK) profile based on relevant simulations, with comparable doses identifiedNew ADVANCE survey findings highlight key patient-reported reasons for accepting long-acting injectable treatment options, including improvement of symptoms/condition, recommendation by a HCP, and ease of use data TEL AVIV, Israel and PARSIPPANY, N.J., Sept. 21, 2024 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals, a U.S. affiliate of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), today presented data informing clinical strategies for switching patients to UZEDY®, an extended-release injectable suspension of risperidone for subcutaneous use every one or two months for the treatment of schizophrenia in adults, from a once-monthly subcutaneous injection of Perseris® (RBP-7000). The results were presented during the 37th Annual European College of Neuropsychopharmacology (ECNP) Congress taking place between September 21-24, 2024, in Milan, Italy. Schizophrenia is a complex medical condition that may require switching from an oral option or between different long-acting injectable options during the patient treatment journey. These data further clinical understanding of optimal treatment strategies when switching to UZEDY from Perseris®. “Schizophrenia patients and healthcare providers rely on evidence-based studies that can help inform their treatment decisions. That is why Teva is dedicated to building on our commitment to neuroscience and schizophrenia and helps provide these clinical insights on UZEDY switching strategies, along with its role in long-acting treatment options,” said Eric Hughes, MD, PhD, Executive Vice President of Global R&D and Chief Medical Officer at Teva. “Up to 80% of schizophrenia patients experience multiple relapses in the first five years, making switching treatments a common experience in the search for optimal treatment. With UZEDY, Teva is building a robust portfolio of research that can help determine if and when it may be the right long-acting option.” In a population pharmacokinetic (PopPK) analysis, simulations were conducted to predict pharmacokinetic (PK) exposures when switching to UZEDY 4-6 weeks after the last injection of once-monthly RBP-7000. The simulation models indicated that switching to UZEDY 4 weeks after the last dose of once-monthly RBP-7000 resulted in comparable PK properties of UZEDY at both the initial exposure and steady state. Comparable doses included UZEDY at 100 mg (once-monthly dosing) or 200 mg (once-every-two-months dosing) to 120 mg of once-monthly RBP-7000.1 Any switching strategy should be determined by clinicians on an individual patient basis, considering factors such as patient preference, scheduling convenience and potential tolerability issues or risk of symptom breakthrough. “Every person living with schizophrenia has unique treatment needs and preferences that may also evolve over time. For my patients, I encourage discussion around key factors like treatment adherence, dosing frequency, symptom control, and rate of relapse which inform what treatment option may be the most appropriate,” said Christoph Correll, MD, Professor of Psychiatry at the Zucker School of Medicine, Hempstead, NY. “For healthcare providers, there is also a significant knowledge gap in the available clinical data on switching patients between the various LAI treatment options, which have differing pharmacokinetic properties and dosing considerations. Insights from studies like these are crucial for researchers and clinicians like myself, as they help us become more informed and better serve our patients.” Additional key data being presented at ECNP 2024 included new quantitative results from the ADVANCE (Attitudes Driving Regional Differences in LAI Antipsychotic Utilization for Schizophrenia Among HCPs, Patients and Caregivers) surveys, including: Among 447 people living with schizophrenia and 375 caregivers, most common patient-reported reasons for accepting an LAI (n=331) were improvement of symptoms/condition with LAIs (68%, n=224), recommendation by their HCP (65%, n=214) and ease of using LAIs versus oral antipsychotics (57%, n=189).1Patients also reported using LAIs due to fewer side effects versus oral antipsychotics (38%, n=127) and to help prevent hospitalization (20%, n=67).1Caregivers (n=229) reported that patients accepted LAIs based on ease of use versus oral antipsychotics (78%, n=178), to help prevent hospitalization (62%, n=143) and perception that LAIs would work better for improving condition/symptoms (62%, n=143).1Among a sample of 791 HCPs from 8 different countries, most HCPs reported that the primary reason for recommending an LAI to a patient was nonadherence to oral medication, with the exception of South Korea where the most common reason was that an LAI would be more efficacious than oral.1The primary reasons cited for not recommending an LAI were patient clinical characteristics and the lack of an available LAI formulation of the patient’s current oral treatment, except for China and South Korea, where the primary reasons were LAI cost to patient and LAI product not marketed, respectively.1 About SchizophreniaSchizophrenia is a chronic, progressive and severely debilitating mental disorder that affects how one thinks, feels and acts.2 Patients experience an array of symptoms, which may include delusions, hallucinations, disorganized speech or behavior and impaired cognitive ability.2,3,4 Approximately 1% of the world’s population will develop schizophrenia in their lifetime, and 3.5 million people in the U.S. are currently diagnosed with the condition.3,4 Although schizophrenia can occur at any age, the average age of onset tends to be in the late teens to the early 20s for men, and the late 20s to early 30s for women. 4 The long-term course of schizophrenia is marked by episodes of partial or full remission broken by relapses that often occur in the context of psychiatric emergency and require hospitalization.4 Approximately 80% of patients experience multiple relapses over the first five years of treatment, and each relapse carries a biological risk of loss of function, treatment refractoriness, and changes in brain morphology.5,6,7 Patients are often unaware of their illness and its consequences, contributing to treatment nonadherence, high discontinuation rates, and ultimately, significant direct and indirect healthcare costs from subsequent relapses and hospitalizations.2,3,4,5,6,7 About UZEDYUZEDY (risperidone) extended-release injectable suspension, for subcutaneous use, is indicated for the treatment of schizophrenia in adults. In clinical trials, UZEDY significantly reduced the risk of schizophrenia relapse.1,8 UZEDY administers risperidone through copolymer technology under license from MedinCell that allows for absorption and sustained release after subcutaneous injection. UZEDY is the only long-acting, subcutaneous formulation of risperidone available in both one- and two-month dosing intervals.8 For full prescribing information, visit https://www.uzedy.com/globalassets/uzedy/prescribing-information.pdf. INDICATION AND USAGE UZEDY (risperidone) extended-release injectable suspension for subcutaneous use is indicated for the treatment of schizophrenia in adults. WARNING: INCREASED MORTALITY IN ELDERLY PATIENTS WITH DEMENTIA-RELATED PSYCHOSISElderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death. UZEDY is not approved for use in patients with dementia-related psychosis and has not been studied in this patient population. See below for additional Important Safety Information. IMPORTANT SAFETY INFORMATION CONTINUED CONTRAINDICATIONS: UZEDY is contraindicated in patients with a known hypersensitivity to risperidone, its metabolite, paliperidone, or to any of its components. Hypersensitivity reactions, including anaphylactic reactions and angioedema, have been reported in patients treated with risperidone or paliperidone. WARNINGS AND PRECAUTIONS Cerebrovascular Adverse Reactions: In trials of elderly patients with dementia-related psychosis, there was a significantly higher incidence of cerebrovascular adverse events (e.g., stroke, transient ischemic attack), including fatalities, in patients treated with oral risperidone compared to placebo. UZEDY is not approved for use in patients with dementia-related psychosis. Neuroleptic Malignant Syndrome (NMS): NMS, a potentially fatal symptom complex, has been reported in association with antipsychotic drugs. Clinical manifestations of NMS are hyperpyrexia, muscle rigidity, altered mental status including delirium, and autonomic instability (irregular pulse or blood pressure, tachycardia, diaphoresis, and cardiac dysrhythmia). Additional signs may include elevated creatine phosphokinase, myoglobinuria (rhabdomyolysis) and acute renal failure. If NMS is suspected, immediately discontinue UZEDY and provide symptomatic treatment and monitoring. Tardive Dyskinesia (TD): TD, a syndrome consisting of potentially irreversible, involuntary, dyskinetic movements, may develop in patients treated with antipsychotic drugs. Although the prevalence of the syndrome appears to be highest among the elderly, especially elderly women, it is impossible to predict which patients will develop the syndrome. Whether antipsychotic drug products differ in their potential to cause TD is unknown. The risk of developing TD and the likelihood that it will become irreversible are believed to increase with the duration of treatment and the cumulative dose. The syndrome can develop, after relatively brief treatment periods, even at low doses. It may also occur after discontinuation. TD may remit, partially or completely, if antipsychotic treatment is discontinued. Antipsychotic treatment, itself, however, may suppress (or partially suppress) the signs and symptoms of the syndrome, possibly masking the underlying process. The effect that symptomatic suppression has upon the long-term course of the syndrome is unknown. If signs and symptoms of TD appear in a patient treated with UZEDY, drug discontinuation should be considered. However, some patients may require treatment with UZEDY despite the presence of the syndrome. In patients who do require chronic treatment, use the lowest dose and the shortest duration of treatment producing a satisfactory clinical response. Periodically reassess the need for continued treatment. Metabolic Changes: Atypical antipsychotic drugs have been associated with metabolic changes that may increase cardiovascular/cerebrovascular risk. These metabolic changes include hyperglycemia, dyslipidemia and body weight gain. While all of the drugs in the class have been shown to produce some metabolic changes, each drug has its own specific risk profile. Hyperglycemia and diabetes mellitus (DM), in some cases extreme and associated with ketoacidosis or hyperosmolar coma or death, have been reported in patients treated with atypical antipsychotics, including risperidone. Patients with an established diagnosis of DM who are started on atypical antipsychotics, including UZEDY, should be monitored regularly for worsening of glucose control. Patients with risk factors for DM (e.g., obesity, family history of diabetes) who are starting treatment with atypical antipsychotics, including UZEDY, should undergo fasting blood glucose (FBG) testing at the beginning of treatment and periodically during treatment. Any patient treated with atypical antipsychotics, including UZEDY, should be monitored for symptoms of hyperglycemia including polydipsia, polyuria, polyphagia and weakness. Patients who develop symptoms of hyperglycemia during treatment with atypical antipsychotics, including UZEDY, should undergo FBG testing. In some cases, hyperglycemia has resolved when the atypical antipsychotic, including risperidone, was discontinued; however, some patients required continuation of antidiabetic treatment despite discontinuation of risperidone. Dyslipidemia has been observed in patients treated with atypical antipsychotics. Weight gain has been observed with atypical antipsychotic use. Monitoring weight is recommended. Hyperprolactinemia: As with other drugs that antagonize dopamine D2 receptors, risperidone elevates prolactin levels and the elevation persists during chronic administration. Risperidone is associated with higher levels of prolactin elevation than other antipsychotic agents. Orthostatic Hypotension and Syncope: UZEDY may induce orthostatic hypotension associated with dizziness, tachycardia, and in some patients, syncope. UZEDY should be used with particular caution in patients with known cardiovascular disease, cerebrovascular disease and conditions which would predispose patients to hypotension and in the elderly and patients with renal or hepatic impairment. Monitoring of orthostatic vital signs should be considered in all such patients, and a dose reduction should be considered if hypotension occurs. Clinically significant hypotension has been observed with concomitant use of oral risperidone and antihypertensive medication. Falls: Antipsychotics, including UZEDY, may cause somnolence, postural hypotension, motor and sensory instability, which may lead to falls and, consequently, fractures or other fall-related injuries. Somnolence, postural hypotension, motor and sensory instability have been reported with the use of risperidone. For patients, particularly the elderly, with diseases, conditions, or medications that could exacerbate these effects, assess the risk of falls when initiating antipsychotic treatment and recurrently for patients on long-term antipsychotic therapy. Leukopenia, Neutropenia and Agranulocytosis have been reported with antipsychotic agents, including risperidone. In patients with a pre-existing history of a clinically significant low white blood cell count (WBC) or absolute neutrophil count (ANC) or a history of drug-induced leukopenia or neutropenia, perform a complete blood count (CBC) frequently during the first few months of therapy. In such patients, consider discontinuation of UZEDY at the first sign of a clinically significant decline in WBC in the absence of other causative factors. Monitor patients with clinically significant neutropenia for fever or other symptoms or signs of infection and treat promptly if such symptoms or signs occur. Discontinue UZEDY in patients with ANC (< 1000/mm3) and follow their WBC until recovery. Potential for Cognitive and Motor Impairment: UZEDY, like other antipsychotics, may cause somnolence and has the potential to impair judgement, thinking and motor skills. Somnolence was a commonly reported adverse reaction associated with oral risperidone treatment. Caution patients about operating hazardous machinery, including motor vehicles, until they are reasonably certain that treatment with UZEDY does not affect them adversely. Seizures: During premarketing studies of oral risperidone in adult patients with schizophrenia, seizures occurred in 0.3% of patients (9 out of 2,607 patients), two in association with hyponatremia. Use UZEDY cautiously in patients with a history of seizures or other conditions that potentially lower the seizure threshold. Dysphagia: Esophageal dysmotility and aspiration have been associated with antipsychotic drug use. Antipsychotic drugs, including UZEDY, should be used cautiously in patients at risk for aspiration. Priapism has been reported during postmarketing surveillance for other risperidone products. A case of priapism was reported in premarket studies of UZEDY. Severe priapism may require surgical intervention. Body temperature regulation. Disruption of the body’s ability to reduce core body temperature has been attributed to antipsychotic agents. Both hyperthermia and hypothermia have been reported in association with oral risperidone use. Strenuous exercise, exposure to extreme heat, dehydration and anticholinergic medications may contribute to an elevation in core body temperature; use UZEDY with caution in patients who experience these conditions. ADVERSE REACTIONS The most common adverse reactions with risperidone (≥5% and greater than placebo) were parkinsonism, akathisia, dystonia, tremor, sedation, dizziness, anxiety, blurred vision, nausea, vomiting, upper abdominal pain, stomach discomfort, dyspepsia, diarrhea, salivary hypersecretion, constipation, dry mouth, increased appetite, increased weight, fatigue, rash, nasal congestion, upper respiratory tract infection, nasopharyngitis and pharyngolaryngeal pain. The most common injection site reactions with UZEDY (≥5% and greater than placebo) were pruritus and nodule. DRUG INTERACTIONS Carbamazepine and other strong CYP3A4 inducers decrease plasma concentrations of risperidone.Fluoxetine, paroxetine, and other strong CYP2D6 inhibitors increase risperidone plasma concentration.Due to additive pharmacologic effects, the concomitant use of centrally-acting drugs, including alcohol, may increase nervous system disorders.UZEDY may enhance the hypotensive effects of other therapeutic agents with this potential.UZEDY may antagonize the pharmacologic effects of dopamine agonists.Concomitant use with methylphenidate, when there is change in dosage of either medication, may increase the risk of extrapyramidal symptoms (EPS) USE IN SPECIFIC POPULATIONS Pregnancy: May cause EPS and/or withdrawal symptoms in neonates with third trimester exposure. There is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to atypical antipsychotics, including UZEDY, during pregnancy. Healthcare providers are encouraged to register patients by contacting the National Pregnancy Registry for Atypical Antipsychotics at 1-866-961-2388 or online at http://womensmentalhealth.org/clinicaland-research-programs/pregnancyregistry/. Lactation: Infants exposed to risperidone through breastmilk should be monitored for excess sedation, failure to thrive, jitteriness and EPS. Fertility: UZEDY may cause a reversible reduction in fertility in females. Pediatric Use: Safety and effectiveness of UZEDY have not been established in pediatric patients. Renal or Hepatic Impairment: Carefully titrate on oral risperidone up to at least 2 mg daily before initiating treatment with UZEDY. Patients with Parkinson’s disease or dementia with Lewy bodies can experience increased sensitivity to UZEDY. Manifestations and features are consistent with NMS. Please see the full Prescribing Information for UZEDY, including Boxed WARNING. About TevaTeva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a global pharmaceutical leader with a category-defying portfolio, harnessing our generics expertise and stepping up innovation to continue the momentum behind the discovery, delivery and expanded development of modern medicine. For over 120 years, Teva’s commitment to bettering health has never wavered. Today, the company’s global network of capabilities enables its 37,000 employees across 58 markets to push the boundaries of scientific innovation and deliver quality medicines to help improve health outcomes of millions of patients every day. To learn more about how Teva is all in for better health, visit www.tevapharm.com. Cautionary Note Regarding Forward-Looking StatementsThis press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. You can identify these forward-looking statements by the use of words such as “should,” “expect,” “anticipate,” “estimate,” “target,” “may,” “project,” “guidance,” “intend,” “plan,” “believe” and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance. Important factors that could cause or contribute to such differences include risks relating to: our ability to successfully develop and commercialize UZEDY (risperidone) extended-release injectable suspension for the treatment schizophrenia; our ability to successfully compete in the marketplace, including our ability to develop and commercialize additional pharmaceutical products; our ability to successfully execute our Pivot to Growth strategy, including to expand our innovative and biosimilar medicines pipeline and profitably commercialize the innovative medicines and biosimilar portfolio, whether organically or through business development; and other factors discussed in our Quarterly Report on Form 10-Q for the second quarter of 2024 and in our Annual Report on Form 10-K for the year ended December 31, 2023, including in the section captioned “Risk Factors.” Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements. ________________________ 1 Data on file. Parsippany, NJ: Teva Neuroscience, Inc.2 Substance Abuse and Mental Health Services Administration. Schizophrenia. https://www.samhsa.gov/mental-health/schizophrenia. Accessed November 2023.3 Velligan DI, Rao S. The epidemiology and global burden of schizophrenia. J Clin Psychiatry. 2023;84(1):MS21078COM5. https://doi.org/10.4088/JCP.MS21078COM5 4 Wander C. (2020). Schizophrenia: opportunities to improve outcomes and reduce economic burden through managed care. The American journal of managed care, 26(3 Suppl), S62–S68. https://doi.org/10.37765/ajmc.2020.43013 5 Emsley, R., & Kilian, S. (2018). Efficacy and safety profile of paliperidone palmitate injections in the management of patients with schizophrenia: an evidence-based review. Neuropsychiatric disease and treatment, 14, 205–223. 6 Emsley, R., Chiliza, B., Asmal, L. et al. (2013) The nature of relapse in schizophrenia. BMC Psychiatry 13, 50. 7 Andreasen, N. C., et al. (2013). Relapse duration, treatment intensity, and brain tissue loss in schizophrenia: a prospective longitudinal MRI study. The American journal of psychiatry, 170(6), 609–615.8 UZEDY™ (risperidone) extended-release injectable suspension, for subcutaneous injection Current Prescribing Information. Parsippany, NJ. Teva Neuroscience, Inc. IR Contacts Ran Meir+1 (267) 468-4475 Yael Ashman+972 (3) 914 8262 Sanjeev Sharma+1 (973) 658 2700 PR Contacts Kelley DoughertyEden Klein+1 (973) 832-2810+972 (3) 906 2645

☝ 点击上方 一键预约 ☝   最新最热的医药健康新闻政策 前九批国家组织药品集中采购品种可替代药品参考监测范围      第一批国家组织药品集中采购中选品种监测范围 序号 集采品种 完全可替代 大部分可替代 一定程度上可替代 1 阿托伐他汀钙口服常释剂型 ★辛伐他汀、★匹伐他汀、 普伐他汀、氟伐他汀、洛伐他汀 ★瑞舒伐他汀 2 瑞舒伐他汀钙口服常释剂型 ★辛伐他汀、★匹伐他汀、 普伐他汀、氟伐他汀、洛伐他汀 ★阿托伐他汀 3 氯吡格雷口服常释剂型 噻氯匹定 ★替格瑞洛 4 厄贝沙坦口服常释剂型 ★奥美沙坦酯、★坎地沙坦酯、★缬沙坦、★替米沙坦、 ★氯沙坦、阿利沙坦酯、 阿齐沙坦、美阿沙坦 ★赖诺普利、★贝那普利、★依那普利、 ★培哚普利、雷米普利、喹那普利、 咪达普利 5 氨氯地平口服常释剂型 ★左氨氯地平 ★硝苯地平、★非洛地平、拉西地平、 尼群地平、贝尼地平、西尼地平、 马尼地平、尼卡地平、★乐卡地平 6 恩替卡韦口服常释剂型 拉米夫定、★阿德福韦酯、替比夫定 ★替诺福韦二吡呋酯、★丙酚替诺福韦、艾米替诺福韦 7 艾司西酞普兰口服常释剂型 ★西酞普兰 多塞平、氯米帕明、噻奈普汀、吗氯贝胺、马普替林、 米安色林、瑞波西汀 ★氟西汀、★帕罗西汀、伏硫西汀、 ★度洛西汀、★舍曲林、氟伏沙明、 安非他酮、曲唑酮、★文拉法辛、 米那普仑、★米氮平、阿戈美拉汀、 阿米替林、圣约翰草提取物 8 帕罗西汀口服常释剂型 多塞平、氯米帕明、噻奈普汀、吗氯贝胺、马普替林、 米安色林、瑞波西汀 ★西酞普兰、★艾司西酞普兰、 ★氟西汀、伏硫西汀、★度洛西汀、 ★舍曲林、氟伏沙明、安非他酮、 曲唑酮、★文拉法辛、米那普仑、 ★米氮平、阿戈美拉汀、阿米替林、 圣约翰草提取物 9 奥氮平口服常释剂型 三氟拉嗪、三氟哌多、 五氟利多、洛沙平、硫利达嗪、哌泊塞嗪、氟哌利多 ★氨磺必利、★阿立哌唑、★利培酮、 帕利哌酮、★氯氮平、★喹硫平、 布南色林、★鲁拉西酮、齐拉西酮、 舒必利、氯丙嗪、氟哌啶醇、 氟奋乃静、奋乃静、癸氟奋乃静、 硫必利、氯普噻吨 10 头孢呋辛酯口服常释剂型 ★头孢克洛、★头孢丙烯 ★头孢拉定、★头孢氨苄、头孢羟氨苄、 ★头孢克肟、★头孢地尼、头孢他美酯、 头孢妥仑匹酯、头孢泊肟酯 11 利培酮口服常释剂型 三氟拉嗪、三氟哌多、 五氟利多、洛沙平、硫利达嗪、 哌泊塞嗪、氟哌利多 ★氨磺必利、★阿立哌唑、★奥氮平、 帕利哌酮、★氯氮平、★喹硫平、 布南色林、★鲁拉西酮、齐拉西酮、 舒必利、氯丙嗪、氟哌啶醇、 氟奋乃静、奋乃静、癸氟奋乃静、 硫必利、氯普噻吨 12 吉非替尼口服常释剂型 埃克替尼、★厄洛替尼 ★阿法替尼、达可替尼、奥希替尼、 伏美替尼、阿美替尼 13 福辛普利口服常释剂型 ★赖诺普利、★贝那普利、 ★依那普利、★培哚普利、 雷米普利、喹那普利、咪达普利 ★奥美沙坦酯、★坎地沙坦酯、 ★缬沙坦、★替米沙坦、★氯沙坦、 阿利沙坦酯、阿齐沙坦、美阿沙坦 14 厄贝沙坦氢氯噻嗪口服常释剂型 奥美沙坦酯氢氯噻嗪、 ★氯沙坦氢氯噻嗪、 替米沙坦氢氯噻嗪、 ★缬沙坦氢氯噻嗪、坎地氢噻 15 赖诺普利口服常释剂型 ★贝那普利、★依那普利、 ★培哚普利、雷米普利、 喹那普利、咪达普利 ★福辛普利 16 替诺福韦二吡呋酯口服常释剂型 拉米夫定、★阿德福韦酯、替比夫定 ★丙酚替诺福韦、艾米替诺福韦 ★恩替卡韦 17 氯沙坦口服常释剂型 阿齐沙坦、美阿沙坦、 ★奥美沙坦酯、★坎地沙坦酯、 ★缬沙坦、★替米沙坦、 ★厄贝沙坦、阿利沙坦酯 ★赖诺普利、★贝那普利、★依那普利、 ★培哚普利、雷米普利、喹那普利、 咪达普利 18 依那普利口服常释剂型 ★贝那普利、★赖诺普利、 ★培哚普利、雷米普利、 喹那普利、咪达普利 ★福辛普利、★奥美沙坦酯、★缬沙坦、 ★坎地沙坦酯、★替米沙坦、★氯沙坦、 阿利沙坦酯、阿齐沙坦、美阿沙坦 19 左乙拉西坦口服常释剂型 奥卡西平、丙戊酸镁、丙戊酸钠、 卡马西平、拉莫三嗪、托吡酯 20 伊马替尼口服常释剂型 氟马替尼 尼洛替尼、达沙替尼 21 孟鲁司特口服常释剂型 普仑司特、扎鲁司特 22 蒙脱石口服散剂 23 培美曲塞注射剂 24 氟比洛芬酯注射剂 双氯芬酸、★布洛芬、★帕瑞昔布、 吡罗昔康、★酮咯酸氨丁三醇 25 右美托咪定注射剂 第二批国家组织药品集中采购中选品种监测范围  序号 集采品种  完全可替代 大部分可替代 一定程度上可替代 1 阿比特龙口服常释剂型 氟他胺、★比卡鲁胺、恩扎卢胺 2 阿德福韦酯口服常释剂型 拉米夫定、替比夫定 ★替诺福韦二吡呋酯、★丙酚替诺福韦、艾米替诺福韦、★恩替卡韦 3 阿卡波糖口服常释剂型 伏格列波糖、★米格列醇 4 阿莫西林口服常释剂型 青霉素V、氨苄西林、 苯唑西林、氯唑西林 5 阿奇霉素口服常释剂型 红霉素、琥乙红霉素、 环酯红霉素、★罗红霉素 地红霉素、泰利霉素、依托红霉、 ★克拉霉素 6 安立生坦片 波生坦 马昔腾坦、利奥西呱 7 奥美沙坦酯口服常释剂型 ★氯沙坦、阿利沙坦酯 ★坎地沙坦酯、★缬沙坦、★替米沙坦、★厄贝沙坦、阿齐沙坦、美阿沙坦 ★福辛普利、★贝那普利、★赖诺普利、 ★培哚普利、雷米普利、喹那普利、 咪达普利 8 比索洛尔口服常释剂型 ★美托洛尔、卡维地洛、 贝凡洛尔、阿罗洛尔、 塞利洛尔 阿替洛尔、★普萘洛尔、尼群洛尔 9 对乙酰氨基酚口服常释剂型 ★布洛芬、萘普生 双氯芬酸、★洛索洛芬、★美洛昔康、 ★依托考昔、★塞来昔布、艾瑞昔布 10 多奈哌齐口服常释剂型 加兰他敏、卡巴拉汀、★美金刚 11 氟康唑口服常释剂型 ★伏立康唑、伊曲康唑、泊沙康唑、 艾沙康唑 12 福多司坦口服常释剂型 羧甲司坦、乙酰半胱氨酸 厄多司坦、美司坦、★氨溴索、 ★溴己新、桉柠蒎 13 格列美脲口服常释剂型 格列本脲 ★格列齐特 格列喹酮、★格列吡嗪 14 甲硝唑口服常释剂型 ★替硝唑、★奥硝唑、 塞克硝唑 左奥硝唑 15 聚乙二醇口服散剂 复方聚乙二醇电解质Ⅰ、 复方聚乙二醇电解质Ⅱ、 复方聚乙二醇电解质Ⅲ、 复方聚乙二醇电解质Ⅳ、硫酸镁、乳果糖 16 坎地沙坦酯口服常释剂型 ★氯沙坦、阿利沙坦酯 阿齐沙坦、美阿沙坦、 ★奥美沙坦酯、★缬沙坦、 ★替米沙坦、 ★厄贝沙坦、阿齐沙坦酯 ★福辛普利、★贝那普利、★赖诺普利、 ★培哚普利、雷米普利、喹那普利、 咪达普利 17 克林霉素口服常释剂型 克林霉素棕榈酸酯、 克林霉素磷酸酯、林可霉素 18 铝碳酸镁咀嚼片 铝镁加 磷酸铝凝胶、复方氢氧化铝 19 美洛昔康口服常释剂型 吡罗昔康 氯诺昔康、★塞来昔布、★依托考昔、 艾瑞昔布、双氯芬酸、★洛索洛芬 20 莫西沙星口服常释剂型 吡哌酸、氧氟沙星、 ★诺氟沙星 ★左氧氟沙星、 ★环丙沙星、洛美沙星、 氟罗沙星、司帕沙星 吉米沙星、奈诺沙星、加诺沙星、安妥沙星 21 曲美他嗪缓释控释剂型 22 索利那新口服常释剂型 托特罗定、奥昔布宁 23 他达拉非片 ★西地那非、伐地那非 24 特拉唑嗪口服常释剂型 阿夫唑嗪、多沙唑嗪 ★坦索罗辛、赛洛多辛 25 替吉奥口服常释剂型 氟尿嘧啶 替加氟、★卡培他滨、曲氟尿苷替匹嘧啶 26 头孢氨苄口服常释剂型 ★头孢拉定、头孢羟氨苄 ★头孢呋辛酯、★头孢克洛、★头孢丙烯、★头孢克肟、★头孢地尼、头孢妥仑匹酯、头孢泊肟酯、头孢他美酯 27 头孢拉定口服常释剂型 ★头孢氨苄、头孢羟氨苄 ★头孢呋辛酯、★头孢克洛、★头孢丙烯、★头孢地尼、头孢妥仑匹酯、★头孢克肟、头孢泊肟酯、头孢他美酯 28 辛伐他汀口服常释剂型 ★匹伐他汀、普伐他汀、 氟伐他汀、洛伐他汀 ★瑞舒伐他汀、★阿托伐他汀 29 异烟肼口服常释剂型 30 吲达帕胺口服常释剂型 氢氯噻嗪、★呋塞米、 ★托拉塞米 美托拉宗、螺内酯、阿米洛利、布美他尼 31 注射用紫杉醇（白蛋白结合型） 紫杉醇脂质体、 ★紫杉醇 ★多西他赛 32 左西替利嗪口服常释剂型 赛庚啶、氯苯那敏、 ★西替利嗪 苯海拉明、★异丙嗪、★氯雷他定、 ★地氯雷他定、卢帕他定、★奥洛他定、 非索非那定、阿伐斯汀、咪唑斯汀、 ★依巴斯汀、★贝他斯汀、依美斯汀 第三批国家组织药品集中采购中选品种监测范围  序号 集采品种  完全可替代 大部分可替代 一定程度上可替代 1 阿那曲唑口服常释剂型 ★来曲唑、依西美坦 2 阿哌沙班口服常释剂型 华法林 ★利伐沙班、艾多沙班、★达比加群酯 3 阿扎胞苷注射剂 4 氨基葡萄糖口服常释剂型 5 氨溴索口服常释剂型 羧甲司坦、乙酰半胱氨酸 ★福多司坦、厄多司坦、美司坦 、 ★溴己新、桉柠蒎 6 奥氮平口腔崩解片 三氟拉嗪、三氟哌多、五氟利多、 洛沙平、硫利达嗪、哌泊塞嗪、 氟哌利多 ★氨磺必利、★阿立哌唑、★利培酮、 帕利哌酮、★氯氮平、★喹硫平、布南色林、 ★鲁拉西酮、齐拉西酮、舒必利、氯丙嗪、 氟哌啶醇、氟奋乃静、奋乃静、癸氟奋乃静、 硫必利、氯普噻吨 7 奥美拉唑口服常释剂型 ★艾司奥美拉唑 ★泮托拉唑、兰索拉唑、雷贝拉唑、艾普拉唑 8 布洛芬缓释控释剂型 右布洛芬、萘普生 ★对乙酰氨基酚、★美洛昔康、双氯芬酸、 ★塞来昔布、★依托考昔、芬布芬、洛索洛芬 9 布洛芬颗粒剂 右布洛芬、萘普生 ★对乙酰氨基酚、★美洛昔康、双氯芬酸、 ★塞来昔布、★依托考昔、芬布芬、洛索洛芬 10 地氯雷他定口服常释剂型 赛庚啶、 氯苯那敏、 ★氯雷他定 ★异丙嗪、苯海拉明、非索非那定、 卢帕他定、★奥洛他定、★西替利嗪、 ★左西替利嗪、阿伐斯汀、咪唑斯汀、 ★依巴斯汀、★贝他斯汀、依美斯汀 11 多潘立酮口服常释剂型 ★莫沙必利、氯波必利、伊托必利 12 二甲双胍缓释控释剂型 苯乙双胍 二甲双胍常释制剂 13 二甲双胍口服常释剂型 苯乙双胍 二甲双胍缓释控释剂型 14 非布司他口服常释剂型 别嘌醇、苯溴马隆 15 非那雄胺口服常释剂型（5mg） 爱普列特 ★度他雄胺 16 非那雄胺口服常释剂型（1mg） 17 氟西汀口服常释剂型 多塞平、氯米帕明、噻奈普汀、 吗氯贝胺、马普替林、米安色林、 瑞波西汀 ★西酞普兰、★艾司西酞普兰、★帕罗西汀、 伏硫西汀、★度洛西汀、★舍曲林、 氟伏沙明、安非他酮、曲唑酮、★文拉法辛、 米那普仑、★米氮平、阿戈美拉汀、阿米替林、 圣约翰草提取物 18 枸橼酸西地那非片 ★他达拉非、伐地那非 19 甲钴胺口服常释剂型 维生素B12、腺苷钴胺 20 卡培他滨口服常释剂型 氟尿嘧啶 替加氟、★替吉奥、曲氟尿苷替匹嘧啶 21 卡托普利口服常释剂型 ★福辛普利、★赖诺普利、★培哚普利、 ★依那普利、雷米普利、喹那普利、 ★贝那普利、咪达普利 22 喹硫平口服常释剂型 三氟拉嗪、三氟哌多、五氟利多、 洛沙平、硫利达嗪、哌泊塞嗪、 氟哌利多 ★奥氮平、★利培酮、帕利哌酮、★阿立哌唑、★氨磺必利、布南色林、★鲁拉西酮、齐拉西酮、舒必利、氟哌啶醇、氯丙嗪、氟奋乃静、奋乃静、癸氟奋乃静、硫必利、氯普噻吨 23 来曲唑口服常释剂型 ★阿那曲唑、依西美坦 24 氯氮平口服常释剂型 三氟拉嗪、三氟哌多、五氟利多、 洛沙平、硫利达嗪、哌泊塞嗪、 氟哌利多 ★奥氮平、★利培酮、帕利哌酮、 ★阿立哌唑、★氨磺必利、★喹硫平、 布南色林、★鲁拉西酮、齐拉西酮、舒必利、氟哌啶醇、氯丙嗪、氟奋乃静、奋乃静、 癸氟奋乃静、硫必利、氯普噻吨 25 美金刚口服常释剂型 ★多奈哌齐、利斯的明、加兰他敏、 卡巴拉汀、丁苯酞、甘露特钠 26 孟鲁司特咀嚼片 普仑司特、扎鲁司特 27 孟鲁司特颗粒剂 普仑司特、扎鲁司特 28 匹伐他汀口服常释剂型 ★辛伐他汀 普伐他汀、氟伐他汀、洛伐他汀、 ★阿托伐他汀、★瑞舒伐他汀 29 普芦卡必利口服常释剂型 30 曲美他嗪口服常释剂型 31 塞来昔布口服常释剂型 艾瑞昔布 ★依托考昔、芬布芬、右布洛芬、★布洛芬、洛索洛芬 32 舍曲林口服常释剂型 多塞平、氯米帕明、噻奈普汀、 吗氯贝胺、马普替林、米安色林、 瑞波西汀 ★西酞普兰、★艾司西酞普兰、★氟西汀、 ★帕罗西汀、伏硫西汀、★度洛西汀、 氟伏沙明、安非他酮、曲唑酮、★文拉法辛、 米那普仑、★米氮平、阿戈美拉汀、阿米替林、 圣约翰草提取物 33 坦洛新（坦索罗辛） 缓释控释剂型 ★特拉唑嗪、阿夫唑嗪、多沙唑嗪、赛洛多辛 34 碳酸氢钠口服常释剂型 35 替格瑞洛口服常释剂型 噻氯匹啶 ★氯吡格雷 36 托法替布口服常释剂型 巴瑞替尼、乌帕替尼 37 维格列汀口服常释剂型 ★沙格列汀、西格列汀、阿格列汀、利格列汀 38 维生素B6口服常释剂型 39 西酞普兰口服常释剂型 ★艾司西酞普兰、多塞平、 氯米帕明、噻奈普汀、吗氯贝胺、 马普替林、米安色林、瑞波西汀 ★氟西汀、★帕罗西汀、伏硫西汀、 ★度洛西汀、★舍曲林、氟伏沙明、 安非他酮、曲唑酮、★文拉法辛、米那普仑、★米氮平、阿戈美拉汀、阿米替林、 圣约翰草提取物 40 西替利嗪口服常释剂型 赛庚啶、氯苯那敏 ★左西替利嗪 苯海拉明、★异丙嗪、★氯雷他定、 ★地氯雷他定、非索非那定、卢帕他定、 ★奥洛他定、阿伐斯汀、咪唑斯汀、 ★依巴斯汀、★贝他斯汀、依美斯汀 41 缬沙坦口服常释剂型 ★氯沙坦、 阿利沙坦酯 坎地沙坦、依普沙坦、★厄贝沙坦 ★奥美沙坦、★替米沙坦、阿齐沙坦、 美阿沙坦 42 盐酸达泊西汀片 43 依托考昔口服常释剂型 艾瑞昔布 ★塞来昔布、芬布芬、右布洛芬 44 乙胺丁醇口服常释剂型 氨硫脲、对氨基水杨酸 45 右佐匹克隆口服常释剂型 佐匹克隆 唑吡坦、扎来普隆、艾司唑仑 46 左乙拉西坦口服液体剂 奥卡西平、丙戊酸镁、丙戊酸钠、卡马西平、拉莫三嗪、托吡酯 47 左乙拉西坦注射用浓溶液 苯巴比妥、丙戊酸钠 48 阿莫西林颗粒剂 青霉素V、氨苄西林 苯唑西林、氯唑西林 49 利奈唑胺口服常释剂型 康替唑胺 50 莫西沙星氯化钠注射剂 氧氟沙星、 诺氟沙星 环丙沙星、★左氧氟沙星、 洛美沙星、帕珠沙星、依诺沙星、 培氟沙星、氟罗沙星、加替沙星 奈诺沙星 51 左氧氟沙星滴眼剂 诺氟沙星滴眼液、氧氟沙星滴眼液、洛美沙星滴眼液、环丙沙星滴眼液 ★莫西沙星滴眼液、加替沙星滴眼液 52 环丙沙星口服常释剂型 吡哌酸、 ★诺氟沙星 ★莫西沙星、奈诺沙星、加诺沙星、 西他沙星、依诺沙星、培氟沙星、氟罗沙星、 氧氟沙星、★左氧氟沙星、洛美沙星、 司帕沙星、加替沙星、吉米沙星、安妥沙星 53 头孢地尼口服常释剂型 ★头孢克肟、头孢妥仑匹酯、 头孢泊肟酯、头孢他美酯 ★头孢呋辛酯、★头孢克洛、★头孢丙烯 54 头孢克洛口服常释剂型 ★头孢呋辛酯、★头孢丙烯 ★头孢拉定、★头孢氨苄、头孢羟氨苄、 ★头孢克肟、★头孢地尼、头孢妥仑匹酯、 头孢泊肟酯、头孢他美酯 55 克拉霉素口服常释剂型 红霉素、琥乙红霉素、环酯红霉素、依托红霉素、★罗红霉素 ★阿奇霉素、地红霉素、泰利霉素 第四批国家组织药品集中采购中选品种监测范围  序号 集采品种  完全可替代 大部分可替代 一定程度上可替代 1 恩曲他滨替诺福韦口服常释剂型 齐多夫定、司他夫定、阿巴卡韦、 替诺福韦、奈韦拉平、依非韦伦、 茚地那韦、利托那韦、 洛匹那韦利托那韦、达芦那韦考比司他、 拉替拉韦、多替拉韦 2 多索茶碱注射剂 氨茶碱 二羟丙茶碱 3 氨溴索注射剂 乙酰半胱氨酸、★溴己新 4 沙丁胺醇吸入剂 左沙丁胺醇、★特布他林 5 氨磺必利口服常释剂型 三氟拉嗪、三氟哌多、五氟利多、 洛沙平、硫利达嗪、哌泊塞嗪、 氟哌利多 ★奥氮平、★利培酮、帕利哌酮、 ★氯氮平、★阿立哌唑、★喹硫平、 布南色林、★鲁拉西酮、齐拉西酮、 舒必利、氟哌啶醇、氯丙嗪、氟奋乃静、 奋乃静、癸氟奋乃静、硫必利、氯普噻吨 6 度洛西汀口服常释剂型 多塞平、氯米帕明、噻奈普汀、 吗氯贝胺、马普替林、米安色林、 瑞波西汀 ★西酞普兰、★艾司西酞普兰、 ★氟西汀、★帕罗西汀、伏硫西汀、 ★舍曲林、氟伏沙明、安非他酮、 曲唑酮、★文拉法辛、米那普仑、 ★米氮平、阿戈美拉汀、阿米替林、 圣约翰草提取物 7 喹硫平缓释控释剂型 三氟拉嗪、三氟哌多、五氟利多、 洛沙平、硫利达嗪、哌泊塞嗪、 氟哌利多 ★氨磺必利、★奥氮平、★利培酮、 帕利哌酮、★阿立哌唑、布南色林、 ★鲁拉西酮、齐拉西酮、舒必利、 氟哌啶醇、氯丙嗪、氟奋乃静、奋乃静、 癸氟奋乃静、硫必利、氯普噻吨 8 吡嗪酰胺口服常释剂型 9 诺氟沙星口服常释剂型 部分喹诺酮、小檗碱 10 头孢丙烯口服常释剂型 ★头孢呋辛酯、★头孢克洛 ★头孢拉定、★头孢氨苄、头孢羟氨苄、★头孢地尼、★头孢克肟、 头孢妥仑匹酯、头孢泊肟酯、头孢他美酯 11 左氧氟沙星口服常释剂型 吡哌酸、氧氟沙星、 ★诺氟沙星 ★环丙沙星、洛美沙星、 依诺沙星、培氟沙星、氟罗沙星、 司帕沙星、加替沙星、吉米沙星、 安妥沙星 ★莫西沙星、奈诺沙星、加诺沙星、 西他沙星 12 伏立康唑口服常释剂型 ★氟康唑、伊曲康唑、泊沙康唑、 艾沙康唑 13 特比萘芬口服常释剂型 14 丙泊酚中/长链脂肪乳注射剂 丙泊酚 美索比妥、羟丁酸钠、 氯胺酮、依托咪酯、咪达唑仑、 艾司氯胺酮 15 氯雷他定口服常释剂型 赛庚啶、氯苯那敏 苯海拉明、★异丙嗪、★地氯雷他定、 ★奥洛他定、卢帕他定、非索非那定、 ★左西替利嗪、★西替利嗪、阿伐斯汀、 咪唑斯汀、★依巴斯汀、★贝他斯汀、 比拉斯汀 16 恩格列净口服常释剂型 达格列净、★卡格列净、 艾托格列净 17 卡格列净口服常释剂型 达格列净、★恩格列净、 艾托格列净 18 格列齐特缓释控释剂型 ★格列美脲、格列本脲、消渴丸 格列喹酮、★格列吡嗪 19 那格列奈口服常释剂型 米格列奈、★瑞格列奈 20 瑞格列奈口服常释剂型 米格列奈、★那格列奈 21 羟苯磺酸钙口服常释剂型 22 普拉克索缓释控释剂型 苯海索、金刚烷胺、多巴丝肼、 左旋多巴、卡左双多巴、司来吉兰、 恩他卡朋、雷沙吉兰 23 普拉克索口服常释剂型 苯海索、金刚烷胺、多巴丝肼、 左旋多巴、卡左双多巴、司来吉兰、 恩他卡朋、雷沙吉兰 24 加巴喷丁口服常释剂型 ★普瑞巴林、卡马西平 25 布洛芬口服常释剂型 右布洛芬、芬布芬 萘普生、★美洛昔康、双氯芬酸、★塞来昔布、★依托考昔、 ★洛索洛芬、氟比洛芬、艾瑞昔布 ★对乙酰氨基酚 26 布洛芬注射剂 ★帕瑞昔布、★氟比洛芬酯 27 洛索洛芬口服常释剂型 ★布洛芬 萘普生、★美洛昔康、双氯芬酸、★塞来昔布、★依托考昔、 氟比洛芬、艾瑞昔布 ★对乙酰氨基酚 28 帕瑞昔布注射剂 ★布洛芬、★氟比洛芬酯 29 普瑞巴林口服常释剂型 ★加巴喷丁、卡马西平 30 艾司奥美拉唑口服常释剂型 ★奥美拉唑 兰索拉唑、艾普拉唑 ★泮托拉唑、雷贝拉唑 31 莫沙必利口服常释剂型 氯波必利、伊托必利、★多潘立酮、 甲氧氯普胺 32 泮托拉唑口服常释剂型 ★奥美拉唑、★艾司奥美拉唑、 兰索拉唑、雷贝拉唑、艾普拉唑 33 泮托拉唑注射剂 ★奥美拉唑、★艾司奥美拉唑、 ★兰索拉唑、雷贝拉唑、艾普拉唑 34 替格瑞洛口服常释剂型 噻氯匹啶 ★氯吡格雷 35 比伐芦定注射剂 36 培哚普利口服常释剂型 ★福辛普利、★赖诺普利、 雷米普利、喹那普利、 ★贝那普利、咪达普利、 ★依那普利 37 替米沙坦口服常释剂型 ★氯沙坦、阿利沙坦酯 ★缬沙坦、★坎地沙坦酯、 ★厄贝沙坦、阿齐沙坦、 美阿沙坦、★奥美沙坦酯 38 缬沙坦氨氯地平口服常释剂型 奥美沙坦酯氨氯地平 39 缬沙坦氢氯噻嗪口服常释剂型 ★氯沙坦氢氯噻嗪 ★厄贝沙坦氢氯噻嗪、坎地氢噻、替米沙坦氢氯噻嗪 奥美沙坦酯氢氯噻嗪 40 奥洛他定滴眼剂 吡嘧司特滴眼液、萘非滴眼液、 色甘酸钠滴眼液 41 玻璃酸钠滴眼剂（0.1%） 聚乙二醇滴眼液、 羧甲基纤维素钠滴眼液（0.5%） 42 玻璃酸钠滴眼剂（0.3%） 聚乙二醇滴眼液、 羧甲基纤维素钠滴眼液（1%） 43 替莫唑胺口服常释剂型 44 硼替佐米注射剂 卡非佐米 45 索拉非尼口服常释剂型 瑞戈非尼、仑伐替尼、培唑帕尼、 依维莫司、去甲斑蝥素、斑蝥酸钠 第五批国家组织药品集中采购中选品种监测范围  序号 集采品种  完全可替代 大部分可替代 一定程度上可替代 1 ω-3鱼油中/长链脂肪乳注射液 多种油脂肪乳(C6-24) 结构脂肪乳(C6-24)、脂肪乳(C14-24)、 中/长链脂肪乳（C6-24）、 中/长链脂肪乳（C8-24）、 中/长链脂肪乳(C8-24Ve)、长链脂肪乳(OO) 2 阿法骨化醇口服常释剂型 ★骨化三醇、维生素D 艾地骨化醇 3 阿立哌唑口服常释剂型 三氟拉嗪、三氟哌多、五氟利多、 洛沙平、硫利达嗪、哌泊塞嗪、 氟哌利多 ★氨磺必利、★奥氮平、★利培酮、 帕利哌酮、★喹硫平、布南色林、 ★鲁拉西酮、齐拉西酮、舒必利、氟哌啶醇、氯丙嗪、氟奋乃静、奋乃静、癸氟奋乃静、 硫必利、氯普噻吨 4 阿昔洛韦口服常释剂型 泛昔洛韦、伐昔洛韦 5 艾司奥美拉唑注射剂 ★奥美拉唑 ★兰索拉唑、艾普拉唑 ★泮托拉唑、雷贝拉唑 6 奥洛他定口服常释剂型 赛庚啶、氯苯那敏 苯海拉明、★异丙嗪、★氯雷他定、 ★地氯雷他定、卢帕他定、非索非那定、 ★左西替利嗪、★西替利嗪、阿伐斯汀、 咪唑斯汀、★依巴斯汀、依美斯汀、 ★贝他斯汀 7 奥沙利铂注射剂 顺铂、卡铂、洛铂、奈达铂 8 贝那普利口服常释剂型 ★赖诺普利、★培哚普利、 ★依那普利、雷米普利、 喹那普利、咪达普利 ★福辛普利 9 贝他斯汀口服常释剂型 赛庚啶、氯苯那敏 阿伐斯汀、咪唑斯汀、 ★依巴斯汀、依美斯汀 苯海拉明、★异丙嗪、★氯雷他定、 ★地氯雷他定、卢帕他定、★奥洛他定、 非索非那定、★左西替利嗪、★西替利嗪 10 苯磺顺阿曲库铵注射剂 阿曲库铵 ★罗库溴铵、维库溴铵 11 比卡鲁胺口服常释剂型 氟他胺 恩扎鲁胺 12 达比加群酯口服常释剂型 ★阿哌沙班 ★利伐沙班、艾多沙班、华法林 13 单硝酸异山梨酯缓释控释剂型 硝酸异山梨酯 14 地西他滨注射剂 15 碘海醇注射剂 碘比醇、碘佛醇、碘普罗胺、 ★碘克沙醇、★碘帕醇、 碘美普尔、复方泛影葡胺 16 碘克沙醇注射剂 碘比醇、碘佛醇、碘普罗胺、 ★碘海醇、★碘帕醇、碘美普尔、复方泛影葡胺 17 度他雄胺软胶囊 爱普列特、★非那雄胺 18 多西他赛注射剂 ★紫杉醇、紫杉醇脂质体 ★紫杉醇（白蛋白结合型） 19 法舒地尔注射剂 尼莫地平 20 复方异丙托溴铵吸入剂 ★异丙托溴铵、噻托溴铵、格隆溴铵 21 格列吡嗪缓释控释剂型 ★格列美脲、格列本脲、 ★格列齐特、消渴丸 格列喹酮、★格列吡嗪（常释剂型） 22 格列吡嗪口服常释剂型 格列喹酮 ★格列美脲、格列本脲、★格列齐特、 消渴丸、★格列吡嗪（控释剂型） 23 格隆溴铵注射液 阿托品、东莨菪碱 24 更昔洛韦注射剂 膦甲酸、缬★更昔洛韦 25 枸橼酸氢钾钠颗粒 26 吉西他滨注射剂 27 兰索拉唑注射剂 ★泮托拉唑、雷贝拉唑、★奥美拉唑、 艾普拉唑、★艾司奥美拉唑 28 乐卡地平口服常释剂型 ★硝苯地平、拉西地平、尼群地平、 贝尼地平、西尼地平、马尼地平、尼卡地平、 ★氨氯地平、★左氨氯地平、★非洛地平 29 利伐沙班口服常释剂型 ★阿哌沙班 艾多沙班、★达比加群酯、华法林 30 硫辛酸注射剂 31 罗哌卡因注射剂 布比卡因、★左布比卡因、★利多卡因、 丁卡因、普鲁卡因、氯普鲁卡因 32 氯化钾缓释控释剂型 枸橼酸钾 33 美托洛尔口服常释剂型 贝凡洛尔、塞利洛尔、尼群洛尔 阿替洛尔、★普萘洛尔、★比索洛尔 34 米格列醇口服常释剂型 ★阿卡波糖、伏格列波糖 35 米索前列醇口服常释剂型 36 帕洛诺司琼注射剂 托烷司琼、★昂丹司琼、格拉司琼、阿扎司琼、多拉司琼、雷莫司琼 37 沙格列汀口服常释剂型 ★维格列汀、西格列汀、阿格列汀 利格列汀 38 文拉法辛缓释控释剂型 多塞平、氯米帕明、噻奈普汀、 吗氯贝胺、马普替林、米安色林、 瑞波西汀 ★西酞普兰、★艾司西酞普兰、★氟西汀、 ★帕罗西汀、伏硫西汀、★度洛西汀、 ★舍曲林、氟伏沙明、安非他酮、曲唑酮、 米那普仑、★米氮平、阿戈美拉汀、阿米替林、 圣约翰草提取物 39 西那卡塞口服常释剂型 40 胸腺法新注射剂 胸腺肽、胸腺五肽 41 异丙嗪口服常释剂型 苯海拉明、赛庚啶、氯苯那敏 42 异丙托溴铵吸入剂 ★复方异丙托溴铵、噻托溴铵 43 脂肪乳氨基酸葡萄糖注射剂 中长链脂肪乳/氨基酸(16)/葡萄糖(16％) 脂肪乳氨基酸(17)葡萄糖(19%) 10%脂肪乳(OO)/5.5%氨基酸(15)/葡萄糖(20%)、脂肪乳(10%)/氨基酸(15)/葡萄糖(20%) 44 中/长链脂肪乳（C8~24 Ve）注射剂 中/长链脂肪乳（C8～24）、中/长链脂肪乳（C6~24） ★ω-3鱼油中/长链脂肪乳、 多种油脂肪乳(C6~24)、结构脂肪乳(C6-24)、 长链脂肪乳(OO)、脂肪乳(C14-24) 45 注射用盐酸苯达莫司汀 卡莫司汀 46 紫杉醇注射剂 ★多西他赛、紫杉醇脂质体 ★紫杉醇（白蛋白结合型） 47 阿奇霉素注射剂 红霉素 ★克拉霉素 48 布地奈德吸入剂 氟替卡松、倍氯米松 49 氟康唑注射剂 ★伏立康唑、泊沙康唑、伊曲康唑、艾沙康唑 50 利奈唑胺葡萄糖注射剂 替考拉宁、万古霉素 51 莫西沙星滴眼剂 ★左氧氟沙星滴眼液、 诺氟沙星滴眼液、 氧氟沙星滴眼液、 洛美沙星滴眼液、 环丙沙星滴眼液、 加替沙星滴眼液 52 替硝唑口服常释剂型 ★甲硝唑 ★奥硝唑、塞克硝唑、左奥硝唑 53 头孢呋辛注射剂 头孢替安、头孢孟多、头孢尼西 ★头孢唑林、头孢拉定、头孢硫脒、 头孢噻吩、★头孢曲松、★头孢他啶、 头孢噻肟、头孢哌酮、头孢匹胺、头孢甲肟、 头孢唑肟、★头孢地嗪 54 头孢曲松注射剂 头孢噻肟、头孢匹胺、头孢甲肟、 头孢唑肟、★头孢地嗪 ★头孢呋辛、头孢替安、头孢孟多、 头孢尼西、★头孢吡肟、头孢匹罗、 头孢噻利、头孢哌酮、★头孢他啶 55 头孢他啶注射剂 ★头孢曲松、头孢噻肟、 头孢哌酮、头孢匹胺、头孢甲肟、 头孢唑肟、★头孢地嗪 ★头孢吡肟、头孢匹罗、头孢噻利 56 头孢唑林注射剂 头孢拉定、头孢硫脒、头孢噻吩 头孢替安、头孢孟多、★头孢呋辛、头孢尼西 57 左氧氟沙星注射剂 氧氟沙星、诺氟沙星 洛美沙星、依诺沙星、培氟沙星、 氟罗沙星、加替沙星 ★莫西沙星、奈诺沙星、帕珠沙星、环丙沙星 第七批国家组织药品集中采购品种可替代药品参考监测范围  序号 集采品种 完全可替代 大部分可替代 一定程度上可替代 1 阿法替尼口服常释剂型 ★厄洛替尼、埃克替尼、 ★吉非替尼、达可替尼 奥希替尼、伏美替尼、阿美替尼 2 阿立哌唑口腔崩解片 三氟拉嗪、三氟哌多、五氟利多、 洛沙平、硫利达嗪、哌泊塞嗪、 氟哌利多 ★氨磺必利、★奥氮平、★利培酮、帕利哌酮、 ★喹硫平、布南色林、★鲁拉西酮、齐拉西酮、 舒必利、氟哌啶醇、氯丙嗪、氟奋乃静、奋乃静、 癸氟奋乃静、硫必利、氯普噻吨 3 昂丹司琼注射剂 托烷司琼、格拉司琼、阿扎司琼、多拉司琼、雷莫司琼 ★帕洛诺司琼 4 奥美拉唑注射剂 ★艾司奥美拉唑 ★兰索拉唑、艾普拉唑、★泮托拉唑、雷贝拉唑 5 奥曲肽注射剂 ★生长抑素 兰瑞肽 6 奥司他韦口服常释剂型 阿比多尔、 法维拉韦、玛巴洛沙韦 7 奥硝唑口服常释剂型 ★甲硝唑 ★替硝唑、塞克硝唑、左奥硝唑 8 吡格列酮口服常释剂型 罗格列酮 9 丙酚替诺福韦口服常释剂型 ★阿德福韦酯、 拉米夫定、 替比夫定 ★替诺福韦二吡呋酯、艾米替诺福韦 10 醋酸钙口服常释剂型 碳酸钙 司维拉姆、碳酸镧 11 单硝酸异山梨酯口服常释剂型 硝酸异山梨酯 12 碘帕醇注射剂 ★碘海醇、碘比醇、碘佛醇、 碘普罗胺、复方泛影葡胺 碘克沙醇 13 厄洛替尼口服常释剂型 ★吉非替尼、埃克替尼 ★阿法替尼、达可替尼、奥希替尼、伏美替尼、 阿美替尼 14 二甲双胍维格列汀口服常释剂型 西格列汀二甲双胍、沙格列汀二甲双胍 15 氟桂利嗪口服常释剂型 桂利嗪 16 氟哌噻吨美利曲辛口服常释剂型 多塞平、马普替林、氯米帕明、噻奈普汀、 吗氯贝胺、瑞波西汀、阿米替林 17 磺达肝癸钠注射剂 18 甲磺酸仑伐替尼胶囊 ★索拉非尼、瑞戈非尼 19 甲泼尼龙口服常释剂型 20 甲泼尼龙注射剂 21 咖啡因注射剂 22 克林霉素磷酸酯注射剂 ★克林霉素、林可霉素 23 拉考沙胺口服常释剂型 奥卡西平、卡马西平 24 来氟米特口服常释剂型 25 利多卡因注射剂 布比卡因、★左布比卡因、丁卡因、普鲁卡因、 氯普鲁卡因 26 罗红霉素口服常释剂型 红霉素、琥乙红霉素、 环酯红霉素、依托红霉素 地红霉素、★克拉霉素、★阿奇霉素 27 罗库溴铵注射剂 维库溴铵 ★顺阿曲库铵、阿曲库铵 28 吗替麦考酚酯口服常释剂型 麦考酚钠 29 美罗培南注射剂 ★比阿培南 厄他培南、亚胺培南西司他丁 30 美托洛尔缓释剂型 贝凡洛尔、塞利洛尔、尼群洛尔 阿替洛尔、★普萘洛尔、★比索洛尔 31 米卡芬净注射剂 卡泊芬净 32 米力农注射剂 氨力农 33 帕立骨化醇注射剂 34 帕洛诺司琼注射剂 托烷司琼、 ★昂丹司琼、 格拉司琼、 阿扎司琼、 多拉司琼、 雷莫司琼 35 普萘洛尔口服常释剂型 ★美托洛尔、阿替洛尔、贝凡洛尔、塞利洛尔、 尼群洛尔 36 舒尼替尼口服常释剂型 培唑帕尼 索凡替尼、★索拉非尼、瑞戈非尼、★伊马替尼 37 特布他林吸入剂 ★沙丁胺醇、左沙丁胺醇 38 替加环素注射剂 无 无 奥马环素、依拉环素 39 替罗非班注射剂型 ★依替巴肽 40 头孢吡肟注射剂型 头孢匹罗 ★头孢曲松、★头孢他啶、头孢噻肟、头孢哌酮、 头孢甲肟、头孢唑肟、头孢匹胺、★头孢地嗪 41 头孢克洛口服液体剂 ★头孢呋辛酯、★头孢丙烯 ★头孢拉定、★头孢氨苄、头孢羟氨苄、 ★头孢地尼、★头孢克肟、头孢妥仑匹酯、 头孢泊肟酯、头孢他美酯 42 头孢克肟颗粒剂 ★头孢地尼、头孢妥仑匹酯、 头孢泊肟酯、头孢他美酯 ★头孢拉定、★头孢氨苄、头孢羟氨苄、 ★头孢呋辛酯、★头孢丙烯 43 头孢克肟口服常释剂型 ★头孢地尼、头孢妥仑匹酯、 头孢泊肟酯、头孢他美酯 ★头孢拉定、★头孢氨苄、头孢羟氨苄、 ★头孢呋辛酯、★头孢丙烯 44 头孢美唑注射剂型 ★头孢西丁、★头孢米诺 45 头孢米诺注射剂型 ★头孢西丁、★头孢美唑 46 硝苯地平缓释剂型 ★硝苯地平控释剂型 拉西地平、尼群地平、贝尼地平、西尼地平、 马尼地平、尼卡地平、★乐卡地平 47 硝苯地平控释剂型 ★硝苯地平缓释剂型 拉西地平、尼群地平、贝尼地平、西尼地平、 马尼地平、尼卡地平、★乐卡地平 48 溴己新注射剂 乙酰半胱氨酸、★氨溴索 49 盐酸鲁拉西酮片 三氟拉嗪、三氟哌多、五氟利多、洛沙平、硫利达嗪、哌泊塞嗪、 氟哌利多 ★氨磺必利、★奥氮平、★阿立哌唑、★利培酮、 帕利哌酮、★喹硫平、布南色林、齐拉西酮、 舒必利、氟哌啶醇、氯丙嗪、氟奋乃静、奋乃静、 癸氟奋乃静、硫必利、氯普噻吨 50 盐酸美金刚缓释胶囊 51 伊班膦酸注射剂 帕米膦酸二钠、氯膦酸二钠、 因卡膦酸二钠 ★唑来膦酸 52 伊立替康注射剂 无 无 无 53 依巴斯汀口服常释剂型 赛庚啶、氯苯那敏 苯海拉明、★异丙嗪、阿伐斯汀、依美斯汀、 ★氯雷他定、★地氯雷他定、卢帕他定、 ★奥洛他定、★左西替利嗪、★西替利嗪、 非索非那定、★贝他斯汀 54 依达拉奉注射剂型 无 无 桂哌齐特 55 依替巴肽注射剂 ★替罗非班 56 依折麦布口服常释剂型 海博麦布 57 注射用替莫唑胺 无 无 无 58 唑来膦酸注射剂 氯膦酸二钠、帕米膦酸二钠、 ★伊班膦酸、因卡膦酸二钠  第八批国家组织药品集中采购品种可替代药品参考监测范围  序号 集采品种 完全可替代 大部分可替代 一定程度上可替代 1 阿加曲班注射剂 无 无 无 2 阿托西班注射剂 无 无 无 3 氨甲环酸注射剂型 氨基己酸 氨甲苯酸 4 氨氯地平阿托伐他汀口服常释剂型 无 无 无 5 丙氨酰谷氨酰胺注射剂 无 无 无 6 丙戊酸钠注射剂 无 无 7 非洛地平缓释控释剂型 ★硝苯地平、拉西地平、尼群地平、贝尼地平、尼卡地平、★氨氯地平、★左氨氯地平、★乐卡地平、西尼地平、马尼地平 8 呋塞米注射剂 ★托拉塞米、布美他尼 9 骨化三醇口服常释剂型 ★阿法骨化醇、维生素D 艾地骨化醇 10 甲钴胺注射剂 维生素B12、腺苷钴胺 11 奥司他韦干混悬剂 阿比多尔、 帕拉米韦、扎那米韦、法维拉韦、玛巴洛沙韦 12 氯沙坦钾氢氯噻嗪口服常释剂型 ★厄贝沙坦氢氯噻嗪、奥美沙坦酯氢氯噻嗪、替米沙坦氢氯噻嗪、★缬沙坦氢氯噻嗪、坎地氢噻 13 米氮平口服常释剂型 氯米帕明、噻奈普汀、吗氯贝胺、马普替林、米安色林、瑞波西汀、圣约翰草提取物 多塞平、★西酞普兰、★艾司西酞普兰、★氟西汀、★帕罗西汀、伏硫西汀、★度洛西汀、★文拉法辛、★舍曲林、氟伏沙明、安非他酮、曲唑酮、米那普仑、阿戈美拉汀、阿米替林 14 那屈肝素（那曲肝素）注射剂 ★依诺肝素、达肝素、贝米肝素 15 生长抑素注射剂 ★奥曲肽 16 酮咯酸氨丁三醇注射剂 ★帕瑞昔布、★氟比洛芬酯 17 托拉塞米注射剂 ★呋塞米、布美他尼 18 熊去氧胆酸口服常释剂型 牛磺熊去氧胆酸 19 盐酸奥普力农注射剂 氨力农 ★米力农 20 依诺肝素注射剂 ★那曲肝素、达肝素、贝米肝素 21 左氨氯地平（左旋氨氯地平）口服常释剂型 ★氨氯地平 ★硝苯地平、★非洛地平、拉西地平、   尼群地平、贝尼地平、西尼地平、马尼地平、尼卡地平、★乐卡地平 22 左布比卡因注射剂 布比卡因 ★罗哌卡因、★利多卡因、丁卡因 23 左卡尼汀注射剂 无 无 无 24 阿莫西林克拉维酸钾口服常释剂型 无 无 无 25 阿莫西林钠克拉维酸钾注射剂 哌拉西林钠舒巴坦钠、★哌拉西林钠他唑巴坦钠、阿莫西林钠舒巴坦钠、氨苄西林钠舒巴坦钠、美洛西林钠舒巴坦钠、替卡西林钠克拉维酸钾 26 氨曲南注射剂 无 无 无 27 奥硝唑注射剂型 ★甲硝唑 替硝唑、左奥硝唑 28 复方磺胺甲噁唑口服常释剂型 联磺甲氧苄啶 29 甲硝唑注射剂型 替硝唑、奥硝唑 左奥硝唑 30 利福平口服常释剂型 利福喷丁、利福布汀 31 头孢地尼颗粒剂 ★头孢克肟、头孢妥仑匹酯、头孢泊肟酯、头孢他美酯 ★头孢呋辛酯、★头孢丙烯、★头孢克洛 32 头孢西丁注射剂型 ★头孢美唑、★头孢米诺 33 头孢地嗪注射剂 头孢噻肟、头孢甲肟、头孢唑肟、头孢匹胺 ★头孢曲松、★头孢他啶、头孢哌酮、   ★头孢呋辛、头孢孟多酯、头孢尼西、头孢替安、   头孢匹罗、★头孢吡肟、头孢噻利 34 比阿培南注射剂 ★美罗培南、厄他培南、亚胺培南西司他丁 35 达托霉素注射剂 无 无 无 36 伏立康唑注射剂 ★氟康唑、泊沙康唑、艾沙康唑、伊曲康唑 37 哌拉西林钠他唑巴坦注射剂 哌拉西林钠舒巴坦钠、美洛西林钠舒巴坦钠 ★阿莫西林钠克拉维酸钾、替卡西林钠克拉维酸钾、阿莫西林钠舒巴坦钠、氨苄西林钠舒巴坦钠、 38 头孢哌酮钠舒巴坦钠注射剂 头孢曲松钠舒巴坦 头孢噻肟钠舒巴坦 头孢哌酮他唑巴坦、头孢噻肟钠他唑巴坦、头孢他啶阿维巴坦、头孢他啶他唑巴坦 39 头孢噻肟注射剂 头孢甲肟、头孢唑肟、头孢匹胺、 ★头孢地嗪 ★头孢呋辛、头孢孟多酯、头孢尼西、头孢替安、   ★头孢曲松、★头孢他啶、头孢哌酮、   头孢匹罗、★头孢吡肟、头孢噻利 【监测范围说明】 1.完全可替代指的是带量采购药品可以完全替代右侧所列的药品，其他类推，给药途径不同的药品不属于监测范围。 2.清单所列化学药品为中文通用名称中主要化学成分部分，不区分酸根盐基和具体剂型；凡主要化学成分与替代清单中的名称一致且给药途径与中选药品相同的化学药品均在监测替代范围（与中选药品适应症完全不同的除外）。 3.清单中未完全列出的与中选药品主要化学成分相同且给药途径相同的其他药品也属于监测范围（与中选药品适应症完全不同的除外），如盐酸左西替利嗪片为盐酸左西替利嗪胶囊\颗粒的完全可替代药品，苯磺酸氨氯地平为马来酸氨氯地平、门冬氨酸氨氯地平的完全可替代药品，阿卡波糖口服常释剂型为阿卡波糖咀嚼片的完全可替代药品，奥氮平口服常释剂型为奥氮平口崩片的完全可替代药品，帕罗西汀口服常释剂型是帕罗西汀缓控释剂型的完全可替代药品，利培酮口服常释剂型是利培酮口服液的完全可替代药品、阿莫西林口服常释剂型是阿莫西林颗粒的完全可替代药品等。 4.品种具体剂型包括： （1）口服常释剂型：普通片剂（片、素片、肠溶片、包衣片、薄膜衣片、糖衣片、浸膏片、分散片、划痕片）、硬胶囊、软胶囊（胶丸）、肠溶胶囊；不包括口腔崩解片（口崩片）； （2）缓释剂型：缓释片、缓释包衣片、缓释胶囊； （3）控释剂型：控释片、控释胶囊； （4）吸入剂：气雾剂、粉雾剂、吸入剂、吸入粉雾剂、干粉吸入剂、粉吸入剂、雾化溶液剂、吸入气雾剂、吸入（用）溶液、吸入（用）混悬液、（鼻用）喷雾剂、鼻吸入气雾剂、雾化吸入用混悬液、吸入（用）气雾剂、雾化液； （5）颗粒剂：颗粒剂、肠溶颗粒剂； （6）口服液体剂：口服溶液剂、口服混悬剂、干混悬剂、口服乳剂、胶浆剂、口服液、乳液、乳剂、胶体溶液、合剂、酊剂、滴剂、混悬滴剂、糖浆剂（含干糖浆剂）； （7）注射剂：注射剂、注射液、注射用溶液剂、静脉滴注用注射液、注射用混悬液、注射液无菌粉末、静脉注射针剂、水针、注射用乳剂、粉针剂、针剂、无菌粉针、冻干粉针。 5. 清单所列化学药品已在国家组织药品集中采购范围内的，标注“★”。 (来源:兴平市医疗保障局） 有需要《前九批国家组织药品集中采购品种可替代药品参考监测范围》（Excel版），请扫描下方二维码添加客服微信咨询，申请加入药闻康策高端会员群获取。 药闻康策 新媒体矩阵微信公众号 点击下方  一键关注 【免责声明】 1.“药闻康策”部分文章信息来源于网络转载是出于传递更多信息之目的，并不意味着赞同其观点或证实其内容的真实性。如对内容有疑议，请及时与我司联系。2.“药闻康策”致力于提供合理、准确、完整的资讯信息，但不保证信息的合理性、准确性和完整性，且不对因信息的不合理、不准确或遗漏导致的任何损失或损害承担责任。3.“药闻康策”所有信息仅供参考，不做任何商业交易或医疗服务的根据，如自行使用“药闻康策”内容发生偏差，我司不承担任何责任，包括但不限于法律责任，赔偿责任。 欢迎转发分享、点赞、点在看